Cargando…
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
Patients with relapsed and refractory multiple myeloma (RRMM) who are triple-class exposed (to an immunomodulatory agent, proteasome inhibitor, and anti-CD38 antibody) have limited treatment options and there is no standard of care. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cel...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213772/ https://www.ncbi.nlm.nih.gov/pubmed/34145225 http://dx.doi.org/10.1038/s41408-021-00507-2 |
_version_ | 1783709924197400576 |
---|---|
author | Jagannath, Sundar Lin, Yi Goldschmidt, Hartmut Reece, Donna Nooka, Ajay Senin, Alicia Rodriguez-Otero, Paula Powles, Ray Matsue, Kosei Shah, Nina Anderson, Larry D. Streetly, Matthew Wilson, Kimberly Le, Hoa Van Swern, Arlene S. Agarwal, Amit Siegel, David S. |
author_facet | Jagannath, Sundar Lin, Yi Goldschmidt, Hartmut Reece, Donna Nooka, Ajay Senin, Alicia Rodriguez-Otero, Paula Powles, Ray Matsue, Kosei Shah, Nina Anderson, Larry D. Streetly, Matthew Wilson, Kimberly Le, Hoa Van Swern, Arlene S. Agarwal, Amit Siegel, David S. |
author_sort | Jagannath, Sundar |
collection | PubMed |
description | Patients with relapsed and refractory multiple myeloma (RRMM) who are triple-class exposed (to an immunomodulatory agent, proteasome inhibitor, and anti-CD38 antibody) have limited treatment options and there is no standard of care. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, demonstrated efficacy in triple-class exposed RRMM patients in the KarMMa trial (NCT03361748). In this retrospective study (KarMMa-RW), patient-level data from triple-class exposed RRMM patients were merged into a single data model and compared with KarMMa using trimmed stabilized inverse probability of treatment weighting. Endpoints included overall response rate (ORR; primary), rate of very good partial response or better (≥VGPR), progression-free survival (PFS), and overall survival (OS). Of 1949 real-world triple-class exposed RRMM patients, 190 received subsequent (index) line of therapy and met KarMMa eligibility criteria (Eligible RRMM cohort). With a median follow-up of 13.3 months in KarMMa and 10.2 months in Eligible RRMM, ORR, and ≥VGPR were significantly improved in KarMMa versus Eligible RRMM (ORR, 76.4% vs 32.2%; ≥VGPR, 57.9% vs 13.7%; both P < 0.0001) as were PFS (11.6 vs 3.5 months; P = 0.0004) and OS (20.2 vs 14.7 months; P = 0.0006). This study demonstrated that ide-cel significantly improved responses and survival compared with currently available therapies in triple-class exposed RRMM. |
format | Online Article Text |
id | pubmed-8213772 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-82137722021-07-01 KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma Jagannath, Sundar Lin, Yi Goldschmidt, Hartmut Reece, Donna Nooka, Ajay Senin, Alicia Rodriguez-Otero, Paula Powles, Ray Matsue, Kosei Shah, Nina Anderson, Larry D. Streetly, Matthew Wilson, Kimberly Le, Hoa Van Swern, Arlene S. Agarwal, Amit Siegel, David S. Blood Cancer J Article Patients with relapsed and refractory multiple myeloma (RRMM) who are triple-class exposed (to an immunomodulatory agent, proteasome inhibitor, and anti-CD38 antibody) have limited treatment options and there is no standard of care. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, demonstrated efficacy in triple-class exposed RRMM patients in the KarMMa trial (NCT03361748). In this retrospective study (KarMMa-RW), patient-level data from triple-class exposed RRMM patients were merged into a single data model and compared with KarMMa using trimmed stabilized inverse probability of treatment weighting. Endpoints included overall response rate (ORR; primary), rate of very good partial response or better (≥VGPR), progression-free survival (PFS), and overall survival (OS). Of 1949 real-world triple-class exposed RRMM patients, 190 received subsequent (index) line of therapy and met KarMMa eligibility criteria (Eligible RRMM cohort). With a median follow-up of 13.3 months in KarMMa and 10.2 months in Eligible RRMM, ORR, and ≥VGPR were significantly improved in KarMMa versus Eligible RRMM (ORR, 76.4% vs 32.2%; ≥VGPR, 57.9% vs 13.7%; both P < 0.0001) as were PFS (11.6 vs 3.5 months; P = 0.0004) and OS (20.2 vs 14.7 months; P = 0.0006). This study demonstrated that ide-cel significantly improved responses and survival compared with currently available therapies in triple-class exposed RRMM. Nature Publishing Group UK 2021-06-18 /pmc/articles/PMC8213772/ /pubmed/34145225 http://dx.doi.org/10.1038/s41408-021-00507-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Jagannath, Sundar Lin, Yi Goldschmidt, Hartmut Reece, Donna Nooka, Ajay Senin, Alicia Rodriguez-Otero, Paula Powles, Ray Matsue, Kosei Shah, Nina Anderson, Larry D. Streetly, Matthew Wilson, Kimberly Le, Hoa Van Swern, Arlene S. Agarwal, Amit Siegel, David S. KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma |
title | KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma |
title_full | KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma |
title_fullStr | KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma |
title_full_unstemmed | KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma |
title_short | KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma |
title_sort | karmma-rw: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213772/ https://www.ncbi.nlm.nih.gov/pubmed/34145225 http://dx.doi.org/10.1038/s41408-021-00507-2 |
work_keys_str_mv | AT jagannathsundar karmmarwcomparisonofidecabtagenevicleucelwithrealworldoutcomesinrelapsedandrefractorymultiplemyeloma AT linyi karmmarwcomparisonofidecabtagenevicleucelwithrealworldoutcomesinrelapsedandrefractorymultiplemyeloma AT goldschmidthartmut karmmarwcomparisonofidecabtagenevicleucelwithrealworldoutcomesinrelapsedandrefractorymultiplemyeloma AT reecedonna karmmarwcomparisonofidecabtagenevicleucelwithrealworldoutcomesinrelapsedandrefractorymultiplemyeloma AT nookaajay karmmarwcomparisonofidecabtagenevicleucelwithrealworldoutcomesinrelapsedandrefractorymultiplemyeloma AT seninalicia karmmarwcomparisonofidecabtagenevicleucelwithrealworldoutcomesinrelapsedandrefractorymultiplemyeloma AT rodriguezoteropaula karmmarwcomparisonofidecabtagenevicleucelwithrealworldoutcomesinrelapsedandrefractorymultiplemyeloma AT powlesray karmmarwcomparisonofidecabtagenevicleucelwithrealworldoutcomesinrelapsedandrefractorymultiplemyeloma AT matsuekosei karmmarwcomparisonofidecabtagenevicleucelwithrealworldoutcomesinrelapsedandrefractorymultiplemyeloma AT shahnina karmmarwcomparisonofidecabtagenevicleucelwithrealworldoutcomesinrelapsedandrefractorymultiplemyeloma AT andersonlarryd karmmarwcomparisonofidecabtagenevicleucelwithrealworldoutcomesinrelapsedandrefractorymultiplemyeloma AT streetlymatthew karmmarwcomparisonofidecabtagenevicleucelwithrealworldoutcomesinrelapsedandrefractorymultiplemyeloma AT wilsonkimberly karmmarwcomparisonofidecabtagenevicleucelwithrealworldoutcomesinrelapsedandrefractorymultiplemyeloma AT lehoavan karmmarwcomparisonofidecabtagenevicleucelwithrealworldoutcomesinrelapsedandrefractorymultiplemyeloma AT swernarlenes karmmarwcomparisonofidecabtagenevicleucelwithrealworldoutcomesinrelapsedandrefractorymultiplemyeloma AT agarwalamit karmmarwcomparisonofidecabtagenevicleucelwithrealworldoutcomesinrelapsedandrefractorymultiplemyeloma AT siegeldavids karmmarwcomparisonofidecabtagenevicleucelwithrealworldoutcomesinrelapsedandrefractorymultiplemyeloma |